With all the discussion about SI, going on on the other
With all the discussion about SI, going on on the other board, JFM has posted a reply that I believe is pertinent to the SI numbers so I am posting it for the boards consideration.
From JFM:
Post sites article in Nature (journal) that states several "substances" with very low SI showed "little" effect on virus replication OR showed SEVERE ADVERSE EFFECT in human patients....
1. WHY WOULDN"T THEY SHOW "LITTLE" effect...THEY HAD VERY LOW SI SCORES!!! IN FACT, All these "Substances" COMBINED did not match BRILACIDIN'S SI SCORE *426*. TO COMPARE THESE SUBSTANCES TO OR ANY SUBSTANCE in competition with BRILACIDIN...the substance being compared (which there are NONE) would be "SI" Score of 426...THERE ARE NO OTHERS! So, the comparative statement is comparing rotten apples to juicy oranges.
2. AGAIN...BRILACIN's SI's 426 SCORE is greater than ALL THOSE SUBSTANCES SI SCORE COMBINED and they showed "Little effect", therefore it is reasonable to expect Brilacidin, with 10X SI score of substances cited,...to show SIGNIFICANTLY MORE EFFECT on Covid viral suppression.
3. SAE COMPARISON? as is noted in quote...those OTHER SUBSTANCES "...led to SAE (severe adverse events and side effects) in human patients."...OK...but BRILACIDIN throughout PHASE II Clinical Trials for 5 Different Indications...BRILACIDIN has NEVER CAUSED a single SAE.
So what these "other" substances do it totally irrelevant to Brilacidin.
Quote:
"...several substances like Remdesivir, Lopinavir and Chloroquine were reported to repress viral replication in vitro. However, these compounds showed little effect on virus replication or led to severe adverse side effects in human patients." Bottom line: is that the
in vitro assays in cells did not predict clinical behavior.
Conclusion:
SUBSTANCES WITH Small SI SCORES showed small SUPRESSION of VIRAL SUPPRESSION in Clincial Trials...therefore Substances (Brilacidin) with EXTREMELY HIGH (HIGHEST) SI SCORE OF POTENTIAL THERAPEUTICS ... will likely demonstate in Clinical Trials EXTREMELY HIGH VIRAL SUPPRESSION in current clinicatl trials...compared to the substances sited.
Thank you for providing a post to further demonstrate the GREAT POTENTIAL of BRILACIDIN vs. Covid-19 IMO soon to be demonstrated in the current Clinical Trials!
10
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Revolutionizing Cookware: The Launch of Hybrid 2.0 Today, everyone's buzzing about ProClad's big reveal—the Hybrid 2.0 Pan. Now, before you roll those skeptical eyes, hear me out. This isn’t your average bit of kitchen fluff; it’s a heavyweight contender stepping into the everyday cooking ring. What they've done here is combine the muscle of stainless steel searing...
Continue Reading
An Ode to Tradition Amid Modern Menswear From the bustling avenues of New York to the storied streets of Paris, Hiromi Asai is showcasing something that strikes a chord deep in the fashion industry's soul. Her Spring/Summer 2027 collection, "Akatsuki — Before the Dawn," takes its rare blend of age-old Japanese textile craftsmanship across the pond to the City of Light....
Continue Reading
An Unexpected Wave of Enthusiasm in Event Industry The Event Industry Power 50 is getting some serious action this year. Over 3,500 votes have already rolled in, smashing last year's numbers with days still left on the clock. It seems like folks can't wait to see their favorite event powerhouses crowned at this year's gala, which kicks off October 27 in New York City....
Continue Reading
Ah, the pharmaceutical game is shifting again, and this time Celltrion USA's putting their chips down with OMLYCLO, the shiny new omalizumab biosimilar. Here we see a product that's not just approved but interchangeable with XOLAIR, making it a front-runner in the allergic and inflammatory conditions battleground. If you're a patient or a provider navigating these murky...
Continue Reading
Investment Gold in Abilene's Storage Sector Diving headfirst into the world of bricks and mortar, the opportunity brewing over in Abilene, Texas, packs a potent punch for anyone keen on beefing up their real estate portfolio with a top-notch asset. We're talking about Spare Feet Self Storage, a slick, Class A self-storage facility, serving the cream of the crop in a...
Continue Reading
Facing the Realities of Aging In Place Alright, let's talk straight. Everyone dreams of staying home in their twilight years, kicking back in their favorite chair with family nearby. But the harsh truth? That comfort comes with a price tag. According to Northwestern Mutual's 2026 Planning & Progress Study, up to 83% of Boomers+ and most other generations fancy the idea of...
Continue Reading
Co-op Living: Not All It's Cracked Up to Be Let me tell you something, buying a co-op in New York City isn't just signing on the dotted line and moving in. Nope, it's a whole damn production. Jeff Namian's book, Thin Walls/Thick Ears, lays it all out with a mix of humor and hard truths, painting a stark picture of NYC co-op living. He's not just telling his own story of...
Continue Reading
An Automotive Feat in R&D Now here's a story that should make waves across the automotive sector. China Automotive Systems, Inc. (NASDAQ: CAAS), a titan of power steering development in China, has nailed it by meeting the ASPICE 4.0 Capability Level 2. That's a big one, folks. Verified by a partnership between a European automaker and UL, this achievement is no fluke....
Continue Reading
Turning the Insurance World on Its Head Just when you think the enterprise software scene is getting predictable, along comes a bit of news to shake things up. Guidewire, a name known in the P&C insurance software world, has roped in a veteran—Dan Brown—who's got more than a quarter-century under his belt shaping product strategies. It’s not just another suit...
Continue Reading
From Ashes to Airwaves Gritty stories of survival often cut deeper than any wonky industry analysis or corporate earnings report. When you've been through the wringer and come out the other side, that experience sticks with you—and for Kim S. Marshall, it ignited something personal yet universal with the #L.A. Rising podcast. Emerging from the 2025 L.A. fires, this...
Continue Reading
Top 5 Most Recently Viewed Articles
Keysight Technologies Reports Optimistic Q4 Results Keysight Technologies, Inc. (NASDAQ: KEYS) has recently made headlines by delivering stellar fourth-quarter earnings results that exceeded market expectations. The company reported quarterly earnings of $1.91 per share, surpassing the consensus estimate of $1.83. In addition, Keysight's quarterly revenue reached $1.42...
Continue Reading
Liberty Defense Set to Revolutionize Security at JFK Liberty Defense Holdings Ltd., a forefront leader in technology for detecting concealed weapons and threats, is thrilled to announce that its innovative HEXWAVE™ systems will be incorporated into the aviation worker screening checkpoints at the New Terminal One at JFK International Airport. This all-international...
Continue Reading
Living Water International Welcomes New Leadership Team Living Water International, a prominent Christian nonprofit renowned for its commitment to sustainable water, sanitation, and hygiene (WASH) solutions, has made significant strides in its leadership structure. The organization proudly announces Dr. Jonathan Wiles as its new Chief Executive Officer, while Dr. Mike...
Continue Reading
Stellantis and IVECO's Exciting Collaboration The commercial vehicles division of Stellantis N.V., known as Stellantis Pro One, has partnered with IVECO, a respected Italian manufacturer, to bring two fully electric light commercial vehicles (LCVs) to the European market. This strategic partnership marks a significant step toward enhancing the electric vehicle landscape...
Continue Reading
Prime Medicine Showcases Groundbreaking Preclinical Research Prime Medicine, Inc. (Nasdaq: PRME), a cutting-edge biotechnology company, is making waves with promising new advancements in genetic therapies. They are gearing up to present their innovative research, focused particularly on Wilson's Disease, at two pivotal scientific conferences. This cutting-edge research...
Continue Reading